[68Ga]-Pentixafor Imaging for Blood Cancers
Trial Summary
What is the purpose of this trial?
The purpose of this study is to determine the uptake of the imaging agent \[68Ga\]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD).
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.
What data supports the effectiveness of the treatment [68Ga]-Pentixafor for blood cancers?
[68Ga]-Pentixafor is effective in imaging certain blood cancers, like lymphomas, by targeting CXCR4 receptors, which are often overexpressed in these cancers. It has shown better diagnostic performance than some existing methods and helps in staging and evaluating treatment responses, especially in lymphomas such as mantle cell lymphoma and marginal zone lymphoma.12345
How does [68Ga]-Pentixafor imaging differ from other blood cancer treatments?
[68Ga]-Pentixafor imaging is unique because it uses a radiopharmaceutical that targets specific receptors, allowing for precise imaging of cancer cells. This method is part of a newer approach in nuclear medicine that uses PET scans to provide detailed images, which can help in early diagnosis and personalized treatment planning.678910
Research Team
Anton Nosov, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
Adults over 18 with certain blood cancers like multiple myeloma, non-Hodgkin's lymphoma, or histiocytic neoplasms can join this trial. It's for MSKCC patients who haven't had treatment yet, those whose treatment didn't work, or if it came back. Women must not be pregnant and everyone should be able to handle a PET/CT scan without issues.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants receive an intravenous bolus of [68Ga]-Pentixafor and undergo PET/CT scans to evaluate uptake dynamics and pharmacokinetics
Follow-up
Participants are monitored for safety and effectiveness after imaging
Treatment Details
Interventions
- [68Ga]-Pentixafor
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Pentixapharm AG
Industry Sponsor
PentixaPharm GmbH
Industry Sponsor